← Back to Screener
Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Price$0.23
Favorite Metrics
Price vs S&P 500 (26W)-92.39%
Price vs S&P 500 (4W)-18.36%
Market Capitalization$8.33M
All Metrics
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)-72.22%
EPS (TTM)$-0.56
10-Day Avg Trading Volume13.91M
EPS Excl Extra (TTM)$-0.56
EPS (Annual)$-0.43
Cash / Share (Quarterly)$0.01
ROA (Last FY)-1990.35%
EBITD / Share (TTM)$-0.42
Cash Flow / Share (Annual)$-0.37
Net Interest Coverage (TTM)-72.26x
ROA (TTM)-412.86%
EPS Incl Extra (Annual)$-0.43
Current Ratio (Annual)0.05x
Quick Ratio (Quarterly)0.03x
3-Month Avg Trading Volume7.60M
52-Week High$33.66
EPS Excl Extra (Annual)$-0.43
26-Week Price Return-88.40%
Quick Ratio (Annual)0.03x
13-Week Price Return-75.90%
Current Ratio (Quarterly)0.05x
Enterprise Value$9.434
Cash / Share (Annual)$0.01
3-Month Return Std Dev261.68%
Net Interest Coverage (Annual)-71.90x
EPS Basic Excl Extra (Annual)$-0.43
EPS Incl Extra (TTM)$-0.56
Revenue / Share (Annual)$0.00
Year-to-Date Return-69.57%
5-Day Price Return-9.90%
EPS Normalized (Annual)$-0.43
Month-to-Date Return7.97%
EBITD / Share (Annual)$-0.42
EPS Basic Excl Extra (TTM)$-0.56
Price vs S&P 500 (13W)-76.59%
Beta0.67x
Revenue / Share (TTM)$0.00
52-Week Low$0.16
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LIMNLiminatus Pharma, Inc. Class A Common Stock | — | — | — | — | $0.23 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Liminatus Pharma is a clinical-stage biopharmaceutical company developing the GCC Vaccine, an immunotherapy targeting cancers that express Guanylyl Cyclase C. The vaccine candidate is currently in Phase II clinical trials for colorectal, pancreatic, gastric, and esophageal cancers.